Stryker Co. (NYSE:SYK) Shares Sold by Telemus Capital LLC

Telemus Capital LLC cut its holdings in shares of Stryker Co. (NYSE:SYK) by 6.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,147 shares of the medical technology company’s stock after selling 77 shares during the period. Telemus Capital LLC’s holdings in Stryker were worth $343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. AE Wealth Management LLC lifted its position in Stryker by 6.5% during the third quarter. AE Wealth Management LLC now owns 13,679 shares of the medical technology company’s stock valued at $3,738,000 after purchasing an additional 833 shares during the period. Wedge Capital Management L L P NC raised its position in shares of Stryker by 16.2% in the third quarter. Wedge Capital Management L L P NC now owns 780 shares of the medical technology company’s stock worth $213,000 after acquiring an additional 109 shares during the period. Naples Global Advisors LLC raised its position in shares of Stryker by 45.7% in the third quarter. Naples Global Advisors LLC now owns 1,608 shares of the medical technology company’s stock worth $440,000 after acquiring an additional 504 shares during the period. Douglas Lane & Associates LLC raised its position in shares of Stryker by 4.1% in the third quarter. Douglas Lane & Associates LLC now owns 1,885 shares of the medical technology company’s stock worth $515,000 after acquiring an additional 74 shares during the period. Finally, Flagship Harbor Advisors LLC raised its position in shares of Stryker by 2.5% in the third quarter. Flagship Harbor Advisors LLC now owns 2,271 shares of the medical technology company’s stock worth $621,000 after acquiring an additional 55 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Up 0.7 %

Shares of NYSE SYK opened at $327.68 on Tuesday. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The stock has a market cap of $124.67 billion, a PE ratio of 39.72, a P/E/G ratio of 2.62 and a beta of 0.89. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $349.74 and a 200 day moving average of $313.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter in the prior year, the company earned $3.00 EPS. Stryker’s revenue was up 11.8% compared to the same quarter last year. As a group, sell-side analysts predict that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.98%. Stryker’s dividend payout ratio (DPR) is 38.79%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SYK. Evercore ISI upped their price objective on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and upped their price objective for the stock from $315.00 to $360.00 in a research report on Wednesday, January 31st. Royal Bank of Canada upped their price target on shares of Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a research report on Monday, April 15th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Finally, Citigroup upped their price target on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $340.45.

Insider Activity

In other news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 3,273 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock valued at $72,845,768 in the last 90 days. Company insiders own 5.50% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.